IFNB1 and Parkinson disease: However, an epidemiological study suggests IFNβ treated MS patients develop Parkinson’s disease (PD)-like symptoms, such as impaired motor function and cognitive deficits, with long term type-I IFN therapy (Manouchehrinia and Constantinescu, 2012).